RxDoctor Payments Data

Merna Matilsky, MD

Family Medicine · Boca Raton, FLNPI 1881614113

Payments from drug & device makers

$3,138in general payments, 2019–2025

Across 62 payments — averaging $50.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$723
  • AstraZeneca$510
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$411
  • Johnson & Johnson$308
  • AbbVie$253
  • Pfizer$140
  • plus $794 from 12 others

What the payments were for

  • Food & beverage$3,138100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,138 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$7,028
Medicare patients
27
Services billed
53

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$51,290
EliquisApixaban37$44,125
MounjaroTirzepatide30$32,428
JardianceEmpagliflozin15$18,709
MyrbetriqMirabegron14$13,401
TradjentaLinagliptin14$10,223
Lacosamide16$2,941
Levothyroxine Sodium170$1,740
Levetiracetam18$1,663
ProgesteroneProgesterone, Micronized39$1,468
Estradiol (Twice Weekly)Estradiol20$1,278
Metoprolol Succinate37$959
Lisinopril156$875
Atorvastatin Calcium72$830
Losartan Potassium102$787

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$723$51,29037 claims
PfizerEliquis$140$44,12537 claims
Lilly USA, LLCMounjaro$61$32,42830 claims
Astellas Pharma US IncMyrbetriq$16$13,40114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →